Fall Micro-Strike: KidneyCAN Asks Congress to Fund Kidney Cancer Research

On Monday, December 1, 2021, KidneyCAN gathered a team of delegates and once again asked Congress to fund kidney cancer research. We are asking for robust funding of the Congressionally Directed Medical Research Programs, and for money specifically directed to kidney cancer research.

In 2016, Congress allocated $0 specifically to kidney cancer research. That number has increased to $135 million in five years — $185 million if this year’s funding goes through — and that’s due to advocacy from the kidney cancer community. Ordinary patients, caregivers, family and friends, doctors and researchers get together and explain to Congress why this money is needed.

This funding isn’t a given from year to year. We have to keep asking for it. This year’s asks are as follows:

KidneyCAN asks Congress:

  • To Maintain the $50 million currently allocated for KCRP for Fiscal Year 2022. *
    To Increase the NIH budget by $3.5 billion for Fiscal Year 2022. **
  • To support the creation of ARPA-H (the Advanced Research Projects Agency – Health) at NIH with an additional $3 billion.
  • To continue supporting legislative initiatives that contribute to robust, sustainable funding for medical research.
  • To continue to incorporate the patient perspective on legislative policy matters.

*The KCRP is designated under the CDMRP.
**The base NIH budget will increase to $46.1 billion. With ARPA-H funding, the NIH funding will be $49.1 billion.

Michael Mariani, PhD, is a kidney cancer researcher at the Geisel School of Medicine at Dartmouth College. He and KidneyCAN President Bryan Lewis meet with Senator Leahy’s office (D-VT) to discuss funding.

Congress passed and the President signed into law a second stopgap funding bill (continuing resolution, or CR) on December 3rd that will keep the government running until Feb. 18, 2022. This will give Congress additional time to work on Fiscal Year 2022 appropriations bills.

A second CR is not ideal for the kidney cancer community, as funding is frozen until new budgets are approved. The longer the CR, the more difficult it is for researchers to do their research work. This results in no new programs of research.

We urge Congress to agree on new funding amounts for defense and non-defense programs, and avoid any further funding delays.

If House and Senate appropriators can agree, the government could be funded in mid-February and new programs can get underway.

WHO WE ARE →

WHAT WE DO →

OUR STORIES →

THE KIDNEY CANCER COMMUNITY →

SCIENTIFIC ADVISORS →

DONATE →

CONTACT →

Latest News

Remembering Ralph: Time Well Spent

Remembering Ralph: Time Well Spent

Ralph Knapp was diagnosed in 2014 with stage IV kidney cancer and used the opportunity to increase research funding and bring hope to patients everywhere. With heavy hearts and profound sadness, we announce the passing of Ralph Knapp, a founder of KidneyCAN and leader of our mission to accelerate...

SPRING ADVOCACY DAYS 2022 →

JOIN OUR COMMUNITY →

RAISING AWARENESS →

BE AN ADVOCATE →

DONATE NOW →

CONTACT →

Latest News

Let’s Get Loud: Spring 2022 Advocacy Days

Let’s Get Loud: Spring 2022 Advocacy Days

On March 7-8, KidneyCAN gathered advocates from all over the United States to ask Congress for robust funding for kidney cancer research through the NIH and CDMRP (Congressionally Directed Medical Research Programs). Read on to hear about our goals for this event and how you can help fund...

Patient Resource Center

UNDERSTANDING YOUR KIDNEY CANCER DIAGNOSIS

BUILDING A CARE TEAM

TREATMENT & TRIAL OPTIONS

LIVING WELL WITH KIDNEY CANCER

KCRS: KIDNEY CANCER RESEARCH SUMMIT →

RESEARCH OPPORTUNITIES →

NEWS →

Latest News

IKCC Report: Retention in Clinical Trials

IKCC Report: Retention in Clinical Trials

The International Kidney Cancer Coalition launched a pilot program to understand the barriers and other considerations that drive the decision to leave a clinical trial and uncover ways to better support patients currently in or considering joining clinical trials. Clinical trials are the key to...

SUPPORT OUR WORK →

FUNDRAISE FOR KIDNEYCAN →

DONATE →

CONTACT →

Latest News

Remembering Ralph: Time Well Spent

Remembering Ralph: Time Well Spent

Ralph Knapp was diagnosed in 2014 with stage IV kidney cancer and used the opportunity to increase research funding and bring hope to patients everywhere. With heavy hearts and profound sadness, we announce the passing of Ralph Knapp, a founder of KidneyCAN and leader of our mission to accelerate...